LYT Overview

Reverse Stock Split Announcement: Lytus Technologies has executed a 1-for-2,500 reverse stock split of its common shares, effective September 26, 2025, on the OTCQB.

Purpose of the Split: The CEO, Dharmesh Pandya, stated that the primary goal of the reverse stock split is to increase the market price of shares to meet NYSE American initial listing requirements, with no impact on shareholders' rights except for fractional shares.

Financial Performance: Lytus Technologies reported a 24% increase in revenue to $12.01 million for the six months ending September 30, 2024, alongside a net profit of $648,972, marking a significant turnaround from a loss in the previous year.

Strategic Growth Initiatives: The company is expanding its broadband services in India and plans further investments in digital infrastructure and customer acquisition to enhance profitability and support long-term growth.

Financial Performance: Lytus Technologies Holdings reported a revenue of $12.01 million for the first half of the fiscal year, with positive operating cash flow of $182,070.

Asset Growth: The company’s total assets increased by 8.3%, reaching $34.17 million as of September 30, 2024, compared to $31.56 million in the same period the previous year.

Precision BioSciences Stock Surge: Shares of Precision BioSciences rose 10.8% to $5.58 in pre-market trading after the U.S. FDA cleared its investigational new drug application for PBGENE-HBV, aimed at treating chronic hepatitis B.

Pre-Market Trading Highlights: Several stocks experienced significant movements in pre-market trading, with notable gainers including NanoVibronix (up 42.3%) and Lytus Technologies (up 36.7%), while losers included Fold Holdings (down 18.8%) and Incyte Corporation (down 15.3%).

Lytus Healthcare Launch: Lytus Technologies has launched Lytus Healthcare to enhance patient care in India, leveraging AI-driven solutions and aiming to address gaps in healthcare accessibility as the sector is projected to grow significantly.

Strategic Financing for Growth: The company secured a Standby Equity Purchase Agreement for up to $100 million to support its expansion efforts, reflecting strong revenue growth and a commitment to investing in next-generation technology solutions.

RH's Stock Performance: RH shares surged 17.1% in pre-market trading after the company reported disappointing third-quarter earnings but raised its revenue guidance, anticipating a 20% to 22% growth in demand for the fourth quarter.

Market Movements: Several stocks experienced significant pre-market fluctuations, with notable gainers including Pearl Holdings Acquisition Corp (+44.1%) and Loop Industries, while Repare Therapeutics saw a sharp decline of 35.8%.